4. Outlook and developments
Current research is therefore focused on two objectives: to ensure that the photosensitizer accumulates selectively and exclusively in the tumor volume to be treated, and to circumscribe the photosensitizer irradiation zone to this same volume .
4.1 Targeting strategies
The first objective can be achieved by developing photosensitizers with a particularly strong affinity for cancer...
The Ultimate Scientific and Technical Reference
This article is included in
Healthcare technologies
This offer includes:
Knowledge Base
Updated and enriched with articles validated by our scientific committees
Services
A set of exclusive tools to complement the resources
Practical Path
Operational and didactic, to guarantee the acquisition of transversal skills
Doc & Quiz
Interactive articles with quizzes, for constructive reading
Outlook and developments
Conclusion
Bibliography
Websites
Haute Autorité de Santé website, information on :
Visudyn® http://www.has-sante.fr/portail/jcms/c_486276/visudyne
Foscan™ http://www.has-sante.fr/portail/jcms/c_1012344/foscan?xtmc==2
...Events
Exhibition: OPTO, Paris, Porte de Versailles, for players in the optics and photonics industry http://www.mesurexpovision.com/les-salons/opto/opto
Standards and norms
- Medical devices – Quality management systems – Requirements for regulatory purposes - ISO 13485 - 2003
Patents
"Preparation of hematoporphyrin dimers and trimers for photodynamic therapy" WO 9000392 A1 19900125
"Preparation of dihydro and tetrahydro derivatives of porphyrins for cancer phototherapy EP337601 A1 19891018
"Radiation-absorbing dyes for treating illnesses assocd. with abnormal vasculature" WO 2001039764 A2 20010607
Directory
Manufacturers – Suppliers – Distributors (non-exhaustive list)
Photosensitizers
Novartis Pharma http://www.novartis.com
DraxisPharma http://www.photofrin.com/
The Ultimate Scientific and Technical Reference
